Acute lymphoblastic leukemia followed by a clonally-unrelated EBV-positive non-Hodgkin lymphoma and a clonally-related myelomonocytic leukemia cutis

2004 ◽  
Vol 42 (4) ◽  
pp. 343-349 ◽  
Author(s):  
Tomasz Szczepa?ski ◽  
Gerard A.M. de Vaan ◽  
Auke Beishuizen ◽  
Jos� Bogman ◽  
Mieke W.J.C. Jansen ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Hodgkin Lymphoma ◽  
Lymphoblastic Leukemia ◽  
Non Hodgkin Lymphoma ◽  
Leukemia Cutis ◽  
Myelomonocytic Leukemia

scholarly journals Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

2020 ◽  
Vol 4 (21) ◽  
pp. 5414-5424 ◽  
Author(s):  
Marcelo C. Pasquini ◽  
Zhen-Huan Hu ◽  
Kevin Curran ◽  
Theodore Laetsch ◽  
Frederick Locke ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Hodgkin Lymphoma ◽  
Real World ◽  
Cellular Therapy ◽  
Lymphoblastic Leukemia ◽  
T Cell Therapy ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Real World Setting

Abstract Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world setting from a cellular therapy registry is presented here. As of January 2020, 511 patients were enrolled from 73 centers, and 410 patients had follow-up data reported (ALL, n = 255; NHL, n = 155), with a median follow-up of 13.4 and 11.9 months for ALL and NHL, respectively. Among patients with ALL, the initial complete remission (CR) rate was 85.5%. Twelve-month duration of response (DOR), event-free survival, and overall survival (OS) rates were 60.9%, 52.4%, and 77.2%, respectively. Among adults with NHL, the best overall response rate was 61.8%, including an initial CR rate of 39.5%. Six-month DOR, progression-free survival, and OS rates were 55.3%, 38.7%, and 70.7%, respectively. Grade ≥3 cytokine release syndrome and neurotoxicity were reported in 11.6% and 7.5% of all patients, respectively. Similar outcomes were observed in patients with in-specification and out-of-specification products as a result of viability <80% (range, 61% to 79%). This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.

Long-Term Effects on Bone Mineral Density of Different Therapeutic Schemes for Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma during Childhood

2010 ◽  
Vol 74 (4) ◽  
pp. 241-250 ◽  
Author(s):  
Sarra Benmiloud ◽  
Mélanie Steffens ◽  
Véronique Beauloye ◽  
Ann de Wandeleer ◽  
Jean-Pierre Devogelaer ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Acute Lymphoblastic Leukemia ◽  
Hodgkin Lymphoma ◽  
Bone Mineral ◽  
Lymphoblastic Leukemia ◽  
Long Term Effects ◽  
Mineral Density ◽  
Non Hodgkin Lymphoma
Sign in / Sign up

Export Citation Format

Share Document